Dyskerin inhibitors belong to a specific class of compounds that target dyskerin, a multifunctional protein primarily known for its involvement in the biogenesis of ribosomal RNA (rRNA) and the modification of small nucleolar RNAs (snoRNAs). Dyskerin is a critical component of the nucleolar small Cajal body-specific RNA protein (snoRNP) complex, which plays a pivotal role in the pseudouridylation of rRNA and snoRNA. Pseudouridylation is a post-transcriptional modification that involves the conversion of uridine to pseudouridine, leading to alterations in RNA structure and function. Dyskerin catalyzes this modification by facilitating the site-specific isomerization of uridine residues within target RNAs. Dyskerin inhibitors, as the name suggests, are a class of molecules designed to interfere with the normal functioning of dyskerin, thereby disrupting its role in pseudouridylation and affecting other cellular processes dependent on this protein.
The mechanism of action of dyskerin inhibitors varies, but they typically exert their effects by either directly binding to dyskerin and preventing its interaction with its RNA substrates or by interfering with the assembly of the snoRNP complex. By inhibiting dyskerin, these compounds disrupt the proper pseudouridylation of rRNA and snoRNA, which can lead to aberrant ribosome biogenesis and altered RNA processing. Dyskerin inhibitors are valuable tools in research aimed at elucidating the role of pseudouridylation and dyskerin in cellular physiology, particularly in processes like ribosome formation, telomere maintenance, and the regulation of non-coding RNAs. Understanding the molecular consequences of dyskerin inhibition can provide valuable insights into the fundamental mechanisms underlying these processes and may have implications in various biological contexts.